ClinicalTrials.gg

Program

Panzyga

Also written as “Panzyga, 10% Intravenous Solution”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Agammaglobulinemia · Polyneuropathies · Purpura, Thrombocytopenic, Idiopathic, led by Octapharma.

Furthest: phase 4, since Mar 6, 20195 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Octapharma52 open or runningphase 4since Mar 6, 2019Mar 6, 2019Dec 31, 2028phase 3 · NCT04929236

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2019First study: phase 4 study in Chronic Immune ThrombocytopeniaFirst studyNCT03866798 · 6 enrolled · United States
  2. Aug 4, 20202 phase 3 studiesNCT04502030, NCT04508530
  3. Jun 11, 2021Phase 3 study in Pediatric Chronic Inflammatory Demyelinating PolyneuropathyNCT04929236 · 30 planned · United States
  4. Sep 30, 2025Phase 3 study in AgammaglobulinemiaNCT07220915 · 360 planned · United States, Bulgaria, Czechia and more

Ahead

  1. Dec 31, 2028Primary completion: phase 3 study in Pediatric Chronic Inflammatory Demyelinating PolyneuropathyNCT04929236
  2. Dec 2029Primary completion: phase 3 study in AgammaglobulinemiaNCT07220915

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220915Agammaglobulinemia · United States, Bulgaria, Czechia and more3RecruitingDec 2029360
NCT04929236Pediatric Chronic Inflammatory Demyelinating Polyneuropathy · United States3RecruitingDec 31, 202830
NCT04508530Pediatric acute-onset neuropsychiatric syndrome · United States, Italy, Sweden3CompletedAug 27, 202471
NCT04502030Leukemia, Lymphocytic, Chronic, B-Cell · United States, Czechia, Denmark and more3CompletedSep 19, 2025247
NCT03866798Chronic Immune Thrombocytopenia · United States4TerminatedSep 19, 20236

How it is read

Names in the registry

  • “Panzyga”, 4 entries
  • “Panzyga, 10% Intravenous Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.